LRMR [NASD]
Larimar Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.38 Insider Own8.50% Shs Outstand39.94M Perf Week3.42%
Market Cap125.31M Forward P/E- EPS next Y-1.10 Insider Trans359.29% Shs Float39.23M Perf Month5.38%
Income-43.50M PEG- EPS next Q-0.40 Inst Own37.80% Short Float0.71% Perf Quarter57.82%
Sales- P/S- EPS this Y17.50% Inst Trans-5.54% Short Ratio0.88 Perf Half Y-15.48%
Book/sh2.73 P/B1.22 EPS next Y36.00% ROA-57.90% Target Price13.00 Perf Year-73.21%
Cash/sh1.46 P/C2.28 EPS next 5Y- ROE-71.50% 52W Range1.53 - 13.69 Perf YTD-69.14%
Dividend- P/FCF- EPS past 5Y35.00% ROI- 52W High-75.23% Beta0.85
Dividend %- Quick Ratio7.40 Sales past 5Y- Gross Margin- 52W Low121.57% ATR0.37
Employees31 Current Ratio7.40 Sales Q/Q- Oper. Margin- RSI (14)58.21 Volatility11.13% 11.39%
OptionableYes Debt/Eq0.00 EPS Q/Q40.00% Profit Margin- Rel Volume0.22 Prev Close3.33
ShortableYes LT Debt/Eq0.00 EarningsAug 11 AMC Payout- Avg Volume314.35K Price3.39
Recom1.70 SMA209.16% SMA5033.36% SMA200-24.59% Volume19,226 Change1.80%
Feb-15-22Downgrade William Blair Outperform → Mkt Perform
Feb-10-21Initiated JMP Securities Mkt Outperform
Feb-01-21Initiated William Blair Outperform $29
Sep-16-22 01:00PM
Sep-14-22 07:04AM
07:01AM
Aug-11-22 04:05PM
Jul-28-22 04:05PM
Jun-28-22 08:00AM
06:05AM
Jun-02-22 08:00AM
May-19-22 08:00AM
May-12-22 07:00AM
Apr-29-22 06:27AM
Apr-13-22 10:40AM
Mar-25-22 07:00AM
Feb-16-22 11:57AM
Feb-14-22 04:01PM
Jan-19-22 06:53AM
Nov-22-21 07:00AM
Nov-20-21 08:40AM
Nov-15-21 07:00AM
Nov-12-21 07:00AM
Sep-16-21 08:00AM
Sep-02-21 04:01PM
Aug-22-21 10:12AM
Aug-19-21 07:00AM
Aug-12-21 07:00AM
Aug-09-21 08:48AM
Jul-23-21 12:00PM
Jul-08-21 04:01PM
Jun-11-21 07:00AM
Jun-05-21 07:55PM
Jun-02-21 10:56PM
Jun-01-21 04:55AM
May-29-21 10:59PM
May-25-21 05:41PM
May-21-21 09:18AM
May-20-21 04:31PM
May-11-21 07:00AM
May-10-21 04:05PM
Mar-04-21 07:00AM
Mar-01-21 03:54AM
Feb-18-21 04:01PM
Dec-16-20 07:23PM
Dec-15-20 08:00AM
Dec-08-20 07:30AM
Nov-13-20 08:00AM
Nov-10-20 08:00AM
Oct-14-20 10:18PM
Oct-13-20 08:00AM
Sep-21-20 09:58AM
Sep-10-20 08:00AM
Sep-01-20 12:47PM
Aug-11-20 07:00AM
Aug-04-20 08:00AM
Jul-28-20 08:00AM
Jul-20-20 04:15PM
May-29-20 04:05PM
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BEN-MAIMON CAROLEPresident and CEOSep 16Buy3.1531,746100,00056,829Sep 19 07:00 AM
Celano MichaelChief Financial OfficerSep 16Buy3.1531,746100,00031,746Sep 19 07:00 AM
Flynn James EDirectorSep 16Buy3.1511,111,10834,999,9904,721,200Sep 20 08:31 PM
Hamilton Thomas EdwardDirectorSep 16Buy3.15317,460999,999507,590Sep 20 06:54 AM